May 2016 - Multiple Sclerosis Awareness Month
Multiple sclerosis treatment and research has long been a focus at the Montreal Neurological Institute and Hospital, known simply as The Neuro, an illustrious member of McGill University and the McGill University Health Centre. Indeed, The Neuro introduced Canada’s first MS clinic. The clinic’s highly specialized staff employs the latest research data and treatment methods in a clinical atmosphere of innovation and progress.
A new study led by researchers at the Montreal Neurological Institute and Hospital of McGill University and the MUHC, gets closer to identifying the mechanisms responsible for multiple sclerosis and makes headway in the search for better treatments.
Low levels of vitamin D significantly increase the risk of developing multiple sclerosis (MS), according to a study led by Dr. Brent Richards of the Lady Davis Institute at the Jewish General Hospital, and published in PLOS Medicine. This finding, the result of a sophisticated Mendelian randomization analysis, confirms a long-standing hypothesis that low vitamin D is strongly associated with an increased susceptibility to MS. This connection is independent of other factors associated with low vitamin D levels, such as obesity.
The 3rd Biogen Idec-sponsored meeting of MS and ALS researchers in Quebec and Montpellier France will be held at the Neuro on October 15 and 16, 2015. This meeting is co-organized by the Neuro and William Camu, Montpelier (France).
The brain is a privileged organ in the body. So vital to life, the brain is protected from alterations elsewhere in the body by a highly regulated gateway known as the blood-brain barrier, which allows only selected molecules to pass through.
What’s new at The Neuro
Research: B cell study may lead to treatment options for MS
Powerful treatment improves patients’ lives and provides new insight into mechanisms of the disease
A new study by Multiple Sclerosis researchers at three leading Canadian centres addresses why bone marrow transplantation (BMT) has positive results in patients with particularly aggressive forms of MS. The transplantation treatment, which is performed as part of a clinical trial and carries potentially serious risks, virtually stops all new relapsing activity as observed upon clinical examination and brain MRI scans. The study reveals how th